Adenocarcinoma has an excellent outcome with pemetrexed treatment in Korean patients: A prospective, multicenter trial

Lung Cancer

Volumn 66, Issue 3, 2009, Pages 338-343

  Lee, Hui Young ^a   Ahn, Myung Ju ^b   Park, Yeon Hee ^b   Ahn, Jin Seok ^b   Kim, Bong Seog ^c   Kim, Hoon Kyo ^d   Kim, Heung Tae ^e   Ryoo, Hun Mo ^f   Bae, Sung Hwa ^f   Lee, Seung Sei ^g   Choi, Kwon ^g   Hong, Dae Sik ^h   Lee, Kyung Hee ⁱ   Kwon, Jung Hye ^j   Choi, In Shil ^k   Kim, Byung Su ^k   Lee, Nam Su ^h   Gong, Soo Jung ^l   Park, Keunchil ^b  

^a Kangwon National University   (South Korea)

^b Samsung Medical Center   (South Korea)

^c Seoul Veterans Hospital   (South Korea)

^d Dongguk University College of Medicine   (South Korea)

^e National Cancer Center   (South Korea)

^f Catholic University of Daegu   (South Korea)

^g Sungkyunkwan University School of Medicine   (South Korea)

^h Soonchunhyang University College of Medicine   (South Korea)

ⁱ Yeungnam University College of Medicine   (South Korea)

^j Hallym University   (South Korea)

^k Seoul National University College of Medicine   (South Korea)

^l Eulji University School of Medicine   (South Korea)

more..

Author keywords

Adenocarcinoma; Korean; Non small cell lung cancer; Pemetrexed

Indexed keywords

CYANOCOBALAMIN; ERLOTINIB; FOLIC ACID; GEFITINIB; GEMCITABINE; IRINOTECAN; NAVELBINE; PEMETREXED; PLATINUM COMPLEX; TAXANE DERIVATIVE; VANDETANIB;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONJUNCTIVITIS; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HISTOPATHOLOGY; HUMAN; KOREA; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RASH; SALVAGE THERAPY; SEX DIFFERENCE; SMOKING HABIT; STOMATITIS; SURVIVAL TIME; THROMBOCYTOPENIA; TREATMENT RESPONSE; VITAMIN SUPPLEMENTATION; VOMITING;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; FEMALE; GLUTAMATES; GUANINE; HUMANS; KOREA; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 69949185941     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2009.02.008     Document Type: Article

References (25)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics. CA Cancer J Clin 57 (2007) 43-66
2. Shin H.R., Won Y.J., and Park J.G. 2002 Annual report of the Korean central cancer registry. Cancer Res Treat 36 (2004) 103-114
3. Govindan R., Page N., Morgensztern D., et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (2006) 4539-4544
4. Ramalingam S., and Belani C.P. State-of-the-art chemotherapy for advanced non-small cell lung cancer. Semin Oncol 31 (2004) 68-74
5. Shepherd F.A., Dancey J., Ramlau R., et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18 (2000) 2095-2103
6. Fossella F.V., DeVore R., Kerr R.N., et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18 (2000) 2354-2362
7. Hanna N., Shepherd F.A., Fossella F.V., et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 22 (2004) 1589-1596
8. Shepherd F.A., Rodrigues Pereira J., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353 (2005) 123-132
9. Shih C., Habeck L.L., Mendelsohn L.G., et al. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 38 (1998) 135-152
10. Thödtmann R., Depenbrock H., Dumez H., et al. Clinical and pharmacokinetic phase I study of multitargeted antifolate (LY231514) in combination with cisplatin. J Clin Oncol 17 (1999) 3009-3016
11. Nakagawa K., Kudoh S., Matsui K., et al. A phase I study of pemetrexed (LY231514) supplemented with folate and vitamin B (12) in Japanese patients with solid tumours. Br J Cancer 95 (2006) 677-682
12. Takimoto C.H., Hammond-Thelin L.A., Latz J.E., et al. Phase I and pharmacokinetic study of pemetrexed with high-dose folic acid supplementation or multivitamin supplementation in patients with locally advanced or metastatic cancer. Clin Cancer Res 13 (2007) 2675-2683
13. Malempati S., Nicholson H.S., Reid J.M., et al. Phase I trial and pharmacokinetic study of pemetrexed in children with refractory solid tumors: The Children's Oncology Group. J Clin Oncol 25 (2007) 1505-1511
14. Manegold C., Gatzemeier U., von Pawel J., et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium ALIMTA) and cisplatin: a multicenter phase II trial. Ann Oncol 11 (2000) 435-440
15. Shepherd F.A., Dancey J., Arnold A., et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma: a study of the National Cancer Institute of Canada Clinical Trials Group. Cancer 92 (2001) 595-600
16. Goedhals L., van Wiyk A.L., Smith B.L., et al. Pemetrexed (Alimta LY231514) demonstrates clinical activity in chemonaive patients with cervical cancer in a phase II single-agent trial. Int J Gyn Cancer 16 (2006) 1172-1178
17. Smit E.F., Mattson K., von Pawel J., et al. ALIMTA (pemetrexed disodium) as second-line treatment of non-small cell lung cancer: a phase II study. Ann Oncol 14 (2003) 455-460
18. Therasse P., Arbuck S.G., Eisenhauer E.A., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 (2000) 205-216
19. Bears A., Garassino I., Cavina R., et al. Pemetrexed single agent in previously treated non-small cell lung cancer: a multi-institutional observational study. Lung Cancer 60 (2008) 240-245
20. Scagliotti G.V., Parikh P., von Pawel J., et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26 (2008) 3543-3551
21. Ciuleanu T.E., Brodowicz T., Belani C.P., et al. Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: a phase III study. Proc Am Soc Cli Oncol 26 (2008) 426s (abstr 8011)
22. Sigmond J., Backus H.H., Wouters D., et al. Induction of resistance to the multitargeted antifolate pemetrexed (ALIMTA) in WiDr human colon cancer cells is associated with thymidylate synthase overexpression. Biochem Pharmacol 66 (2003) 431-438
23. Ceppi P., Volante M., Saviozzi S., et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase. Cancer 107 (2006) 1589-1596
24. Park J., Park B.B., Kim J.Y., et al. Gefitinib (ZD1839) monotherapy as a salvage regimen for previously treated advanced non-small cell lung cancer. Clin Cancer Res 10 (2004) 4383-4388
25. Ahn M.J., Park B.B., Ahn J.S., et al. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer. Clin Cancer Res 14 (2008) 3860-3866